Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Colorcon
Dow
McKesson
Harvard Business School

Last Updated: June 26, 2022

VYLEESI (AUTOINJECTOR) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Vyleesi (autoinjector), and when can generic versions of Vyleesi (autoinjector) launch?

Vyleesi (autoinjector) is a drug marketed by Palatin Technologies and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-nine patent family members in twenty-five countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this compound. Additional details are available on the bremelanotide acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Vyleesi (autoinjector)

Vyleesi (autoinjector) will be eligible for patent challenges on June 21, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 21, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for VYLEESI (AUTOINJECTOR)
International Patents:79
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:VYLEESI (AUTOINJECTOR) at DailyMed
Drug patent expirations by year for VYLEESI (AUTOINJECTOR)
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VYLEESI (AUTOINJECTOR)
Generic Entry Date for VYLEESI (AUTOINJECTOR)*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for VYLEESI (AUTOINJECTOR)

US Patents and Regulatory Information for VYLEESI (AUTOINJECTOR)

VYLEESI (AUTOINJECTOR) is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VYLEESI (AUTOINJECTOR) is See Plans and Pricing.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VYLEESI (AUTOINJECTOR)

Uses of bremelanotide in therapy for female sexual dysfunction
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

Compositions and methods for treatment of sexual dysfunction
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Uses of bremelanotide in therapy for female sexual dysfunction
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

Uses of bremelanotide in therapy for female sexual dysfunction
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

FDA Regulatory Exclusivity protecting VYLEESI (AUTOINJECTOR)

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Moodys
Medtronic
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.